Prevalence of Selected Single-Nucleotide Variants in Patients with Neuroendocrine Tumors—Potential Clinical Relevance
Open Access
- 21 September 2022
- journal article
- research article
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 11 (19) , 5536
Abstract
Introduction: The genetic basis of neuroendocrine tumors (NETs), whose incidence is continuously increasing, is still not fully defined. The majority of NETs are sporadic, and only a small percentage occur as part of hereditary genetic syndromes. However, the associations of multiple genetic variants have been found as clinically relevant in several neoplasms. The aim of this study was to evaluate whether selected, literature-based genetic variants may have a potential role in NET susceptibility and clinical outcome in Polish patients. Materials/methods: A total of 185 patients recruited from one clinical center were enrolled. In the first part of the study, the molecular analysis including four single-nucleotide variants (rs8005354 (DAD1, NM_001344 intronic T/C substitution), rs2069762 (T/G substitution in the promoter region of the IL2 NM_000586), rs3731198 (CDKN2A, NM_000077 intronic A/G substitution), and rs1800872 (C/A substitution in the promoter region of the IL10 NM_000572)) was performed in 107 participants (49 patients with NETs with different primary site NETs and a control group of 58 healthy adult volunteers). In the second stage, the same single-nucleotide polymorphisms (SNPs) were assessed in 127 patients with NET and analyzed in terms of clinical data (primary site, serum CgA concentration, and metastatic disease). Results: The analysis of homozygotes revealed a statistically significant higher prevalence of TT homozygotes of variant rs3731198 in the control group (p = 0.0209). In NET patients, there was a statistically significant higher prevalence of GG homozygotes of variant rs1800872 (p = 0.003). There was a statistically significant correlation between the rs3731198 variant and lymph node metastases (p = 0.0038 with Bonferroni correction). Conclusions: Our study indicates that GG homozygotes of variant rs1800872 are more often observed in NET patients, while TT homozygotes of variant rs3731198 are less frequent in this group. The rs3731198 variant may be related to an increased risk of lymph node metastasis. Further, larger multicenter studies are warranted to evaluate the potential genetic factors of sporadic NETs.Keywords
Funding Information
- Ministry of Science and Higher Education (N41/DBS/000085)
This publication has 31 references indexed in Scilit:
- Association between two interleukin-2 gene polymorphisms and cancer susceptibility: a meta-analysisOncoTargets and Therapy, 2016
- Lack of association between interleukin-2 (IL-2) gene rs2069762 polymorphism and cancer risk: a meta-analysis2015
- Interleukin-2 Gene Polymorphisms and Prognosis of Breast CancerGenetic Testing and Molecular Biomarkers, 2013
- The Interleukin-10 Promoter Polymorphism rs1800872 (-592C>A), Contributes to Cancer Susceptibility: Meta-Analysis of 16 785 Cases and 19 713 ControlsPLOS ONE, 2013
- Genetic associations with sporadic neuroendocrine tumor riskCarcinogenesis, 2011
- IL-2 −330 T/G SNP and serum values—potential new tumor markers in neuroendocrine tumors of the gastrointestinal tract and pancreas (GEP-NETs)Journal of Molecular Medicine, 2010
- Promoter polymorphisms of IL2, IL4, and risk of gastric cancer in a high‐risk Chinese populationMolecular Carcinogenesis, 2008
- High‐resolution analysis of genetic alterations in small bowel carcinoid tumors reveals areas of recurrent amplification and lossGenes, Chromosomes and Cancer, 2008
- Mice Lacking Dad1, the Defender against Apoptotic Death-1, Express Abnormal N-Linked Glycoproteins and Undergo Increased Embryonic ApoptosisDevelopmental Biology, 2000
- Molecular cloning of a human cDNA encoding a novel protein, DAD1, whose defect causes apoptotic cell death in hamster BHK21 cells.Molecular and Cellular Biology, 1993